Analysis of Revenues
Paying user area
Try for free
Baxter International Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Return on Assets (ROA) since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Baxter International Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Baxter International Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BioScience | |||||||||||
| Medical Products | |||||||||||
| Net sales |
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
- BioScience Segment Revenue
- The revenue for the BioScience segment shows a steady upward trend from 2011 to 2014. The values increased each year from 6,053 million USD in 2011 to 6,699 million USD in 2014. However, there is no data available for 2015, which precludes analysis of the most recent year for this segment.
- Medical Products Segment Revenue
- The Medical Products segment exhibits consistent growth from 2011 through 2014. Revenue rose from 7,840 million USD in 2011 to 9,972 million USD in 2014, marking a substantial increase over the four-year period. In 2015, revenue remained nearly flat compared to 2014, showing a negligible decrease to 9,968 million USD.
- Total Net Sales
- Total net sales increased consistently from 13,893 million USD in 2011 to 16,671 million USD in 2014, indicating overall company growth during this period. However, in 2015, net sales decreased significantly to 9,968 million USD, a sharp decline from the previous year. This drop corresponds exactly with the Medical Products segment revenue figure for that year, suggesting that data for BioScience in 2015 is missing or excluded, which impacts the comprehensiveness of the total sales figure for 2015.
- Overall Insights
- From 2011 through 2014, both segments and total net sales demonstrated positive growth trends, with Medical Products showing a particularly pronounced increase. The stability in 2015 for Medical Products contrasts with the missing data for BioScience and the consequent sharp decline in total net sales, which implies incomplete reporting or potential structural changes affecting reported figures. The absence of 2015 data for BioScience limits the ability to conclusively determine whether the decline in total net sales reflects actual business performance or data omission.